Kamel Abou Hussein, Medical Oncologist, Director of Breast Cancer Clinical Trials, and Co-Director of the Janet Knowles Breast Cancer Center at MD Anderson Cancer Center at Cooper, shared a post on LinkedIn:
“How can we optimize treatment for HR+, HER2- breast cancer with CDK4/6 inhibitors?
Join me and experts Drs. Sara Hurwitz , Carlos Barrios, and Eleonora Teplinsky for a live & virtual PVI, PeerView Institute for Medical Education symposium in collaboration with Living Beyond Breast Cancer:
“Key Steps to Success With CDK4/6 Inhibition in Early Through Metastatic HR+, HER2- Breast Cancer: Stratification, Selection, Sequencing, and Specialty Management”
Wednesday, Dec 10, 2025 | 6:30–8:30 PM CST
San Antonio Marriott River Center, San Antonio, TX | Online participation available
We’ll dive into how CDK4/6 inhibitors are transforming outcomes for patients across the disease spectrum. Expect actionable strategies on:
- Risk stratification & precision treatment selection
- Sequencing therapies effectively
- Proactive AE management to boost adherence & quality of life
Whether in person or online, you’ll walk away with practical insights to apply immediately in your practice.
More posts about Breast Cancer.
